CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled / 20 target
Drug / intervention
Obinutuzumabdrug
Likely dose
Obinutuzumab 1gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04983888
NCT04983888Phase 2CompletedUpdate Overdue (0.4/mo)Completion was 12mo ago
CompareCT.gov

A Single-center, Phase 2 Open-label Trial Evaluating the Efficacy and Safety of OBINUTUZUMAB in Treatment of Immunosuppression-dependent or Immunosuppression/Treatment-resistant Primary FSGS, or Contraindication/Patient Refusal to Take High Dose Corticosteroids

Mayo Clinic·interventional·Posted Jul 30, 2021·Updated Jun 25, 2026

In Brief

A Phase 2 clinical trial evaluating Obinutuzumab for Primary Focal Segmental Glomerulosclerosis. Completed, enrolled 20 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of Obinutuzumab in inducing complete or partial remission of proteinuria.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Focal Segmental Glomerulosclerosis
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedJul 30, 2021
Enrollment StartNov 17, 2021
Primary CompletionJun 16, 2025
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 4.9 years ago

Arms & Interventions

Primary Focal Segmental Glomerulosclerosis (FSGS)experimental

Subjects with immunosuppression-dependent or immunosuppression/treatment-resistant primary FSGS or contraindication/patient refusal to take high dose corticosteroids, will receive obinutuzumab 1 gram on day 1 and 1 gram on day 15, given intravenously and then an identical course at 6 months.

Drug: Obinutuzumab

Interventions

Obinutuzumabdrug

1g IV on day one and 1 g IV on day 15, followed by identical course at month 6